This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gossett, K. A. Articles by Dean, J. H. Search for Related Content PubMed PubMed Citation Articles by Gossett, K. A. Articles by Dean, J. H. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Clinical Pathologic Alterations Associated with Subcutaneous Administration of Recombinant Human Interleukin-4 to Cynomolgus Monkeys

Department of Toxicology, Drug Safety Assessment

Thomas A. Barbolt

Department of Toxicology, Drug Safety Assessment

Joel B. Cornacoff

Department of Toxicology, Drug Safety Assessment

David J. Zelinger

Department of Preclinical and Analytical Statistics, Sterling Winthrop Pharmaceuticals Research Division, Rensselaer, New York 12144

Jack H. Dean

Department of Toxicology, Drug Safety Assessment

Recombinant human interleukin 4 (rhuIL-4) is a candidate for the treatment of refractory cancer based on its potential to enhance immune function. Recombinant human IL-4 was administered subcutaneously at 0, 1, 5, or 25 µg/kg/day for 28 days with a 14-day recovery to male and female cynomolgus monkeys as part of the preclinical safety evaluation. Clinical pathologic changes related to treatment with rhuIL-4 were evidence of consumptive coagulopathy, erythrocyte fragmentation, lymphocytosis, and lymphocyte morphologic changes indicative of marked antigenic or mitogenic stimulation, mild eosinophilia and neutrophilia, hypoalbuminemia, hypocholesterolemia, and hypertriglyceridemia. Based on data obtained after the 14-day recovery period, the clinical pathologic changes associated with rhuIL-4 administration were considered to be reversible.

Key Words: Toxicity • cancer • neoplasia • treatment • nonhuman primate • hematology • clinical chemistry

• 1. Anderson TD and Hayes TJ (1989). Toxicity of human recombinant interleukin-2 in rats. Lab. Invest 60: 331–346.[Web of Science][Medline] [Order article via Infotrieve]
• 2. Andus T, Geiger T, Hirano T, Kishimoto T, Tran-Thi T-A, Decker K, and Heinrich PC (1988). Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. Eur. J. Biochem 173: 287–293.[Web of Science][Medline] [Order article via Infotrieve]
• 3. Arai K, Lee F, Miyajima A, Miyatake S, Arai N, and Yokota T (1990). Cytokines: Coordinators of immune and inflammatory responses. Annu. Rev. Bio chem 59: 783–836.
• 4. Argiles JM, Lopez-Soriano FJ, Evans RD, and Williamson DH (1989). Interleukin-1 and lipid metabolism in the rat. Biochem. J 259: 673–678.[Web of Science][Medline] [Order article via Infotrieve]
• 5. Barbolt TA, Gossett KA, and Cornacoff JB (1991). Histomorphologic observations for cynomolgus monkeys after subchronic subcutaneous injection of recombinant human interleukin-4. Toxicol. Pathol 19: 251–257.[Abstract/Free Full Text]
• 6. Beutler B and Cerami A (1988). An endogenous mediator of cellular catabolism and shock. Adv. Inflam. Res 12: 23–32.
• 7. Broxmeyer HE, Lu L, Cooper S, Tushinski R, Mochizuki D, Rubin BY, Gillis S, and Williams DE (1988). Synergistic effects of purified recombinant human and murine B cell growth factor/IL-4 on colony formation in vitro by hematopoietic progenitor cells. Multiple actions. J. Immunol 141: 3852–3862.[Abstract]
• 8. Castel JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, and Heinrich PC (1988). Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 232: 347–350.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 9. Evans RD, Argiles JM, and Williamson DH (1989). Metabolic effects of tumour necrosis factor- (cachectin) and interleukin-1. Clin. Sci 77: 357–364.[Web of Science][Medline] [Order article via Infotrieve]
• 10. Hart PH, Burgess DR, Vitti GF, and Hamilton JA (1989). Interluekin-4 stimulates human monocytes to produce tissue-type plasminogen activator. Blood 74: 1222–1225.[Abstract/Free Full Text]
• 11. Ishizaka A, Joh K, Shibata R, Wagatsuma U, Nakanishi M, Tomizawa K, Kojima K, Kandil E, Sakiyama Y, and Matsumoto S (1990). Regulation of IgE and IgG4 synthesis in patients iwth hyper IgE syndrome. Immunology 70: 414–416.[Web of Science][Medline] [Order article via Infotrieve]
• 12. Le J and Vilcek J (1987). Tissue necrosis factor and interleukin 1: Cytokines with multiple overlapping biological activities. Lab. Invest 56: 234–248.[Web of Science][Medline] [Order article via Infotrieve]
• 13. Le J and Vilcek J (1989). Interleukin 6: A multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab. Invest 61: 588–602.[Web of Science][Medline] [Order article via Infotrieve]
• 14. London L and McKearn JP (1990). The dual regulatory role of interleukin 4 is mediated through a direct effect on the target cell. Exp. Hematol 18: 1059–1063.[Web of Science][Medline] [Order article via Infotrieve]
• 15. Marder VJ (1983). Consumptive thrombohemorrhagic disorders. In: Hematology, WJ Williams, E Beutler, AJ Erslev, and MA Lichtman (eds). McGraw-Hill, New York, pp. 1433–1461.
• 16. Migliaccio AR and Migliaccio G (1990). The control of proliferation and differentiation of early erythroid progenitors. Biotherapy 2: 299–303.[CrossRef][Medline] [Order article via Infotrieve]
• 17. O'Garra A, Umland S, De France T, and Christiansen J (1988). B-cell factors are pleotropic. Immunol. Today 9: 45–54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 18. Peschel C, Paul WE, Ohara J, and Green I (1987). Effects of B cell stimulatory factor-1/interleukin 4 on hematopoietic progenitor cells. Blood 70: 254–263.[Abstract/Free Full Text]
• 19. Prinz JC, Baur X, Mazur G, and Rieber EP (1990). Allergen-directed expression of Fc receptors for IgE (CD23) on human T lymphocytes is modulated by interleukin 4 and interferon-. Eur. J. Immunol 20: 1259–1264.[Web of Science][Medline] [Order article via Infotrieve]
• 20. Rennick D, Yang G, Muller-Sieburg C, Smith C, Arai N, Takabe Y, and Gemmell L (1987). Interleukin 4 (B-cell stimulatory factor 1) can enhance or antagonize the factor-dependent growth of hematopoietic progenitor cells. Proc. Natl. Acad. Sci. USA 84: 6889–6893.[Abstract/Free Full Text]
• 21. Rosenzweig IB, Wiebe DA, Hank JA, Albers JJ, Adolphson JL, Borden E, Shrago ES, and Sondel PM (1990). Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein. Biotherapy 2: 193–198.[CrossRef][Medline] [Order article via Infotrieve]
• 22. Sato T, Misago M, Tsukada J, Kikuchi M, Oda S, Chiba S, and Eto S (1990). Effect of interleukin-4 on the growth of granulocyte-macrophage progenitor cells stimulated by hematopoietic growth factors. J. UOEH 12: 163–174.[Medline] [Order article via Infotrieve]
• 23. Sokal RR and Rohlf FJ (1981). Biometry, 2nd ed. W. H. Freeman, New York.
• 24. Street NE and Mosmann TR (1990). IL4 and IL5: The role of two multifunctional cytokines and their place in the network of cytokine interactions. Biotherapy 2: 347–362.[CrossRef][Medline] [Order article via Infotrieve]
• 25. Szabo G and Miller-Graziano CL (1990). Induction and regulation of monocyte procoagulant activity. Transplantation 50: 301–309.[Web of Science][Medline] [Order article via Infotrieve]
• 26. Tepper RI, Levinson DA, Stanger BZ, Campos-Torres J, Abbas AK, and Leder P (1990). IL-4 induces allergic-like inflammatory disease and alter T cell development in transgenic mice. Cell 62: 457–467.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 27. Tepper RI, Pattengale PK, and Leder P (1989). Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503–512.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• 28. Tocco-Bradley R, Georgieff M, Jones CT, Moldawer LL, Dinarello CA, Blackburn GL, and Bistrian BR (1987). Changes in energy expenditure and fat metabolism in rats infused with interleukin-1. Eur. J. Clin. Invest 17: 504–510.[Web of Science][Medline] [Order article via Infotrieve]
• 29. Vellenga E, Wolf JTM de, Beentjes JAM, Esselink MT, Smit JW, and Halie MR (1990). Divergent effects of interleukin-4 (IL-4) on the granulocyte colony-stimulating factor and IL-3 supported myeloid colony formation from normal and leukemic bone marrow cells. Blood 75: 633–637.[Abstract/Free Full Text]
• 30. Vercelli D, Jabara HH, Lee B-W, Woodland N, Geha RS, and Leung DYM (1988). Human recombinant interleukin 4 induces FceR2/CD23 on normal human monocytes. J. Exp. Med 167: 1406–1416.[Abstract/Free Full Text]

Toxicologic Pathology, Vol. 21, No. 1, 46-53 (1993)
DOI: 10.1177/019262339302100106


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. J. Herzyk, P. J. Bugelski, T. K. Hart, and P. J. Wier Preclinical Safety of Recombinant Human Interleukin-18 Toxicol Pathol, August 1, 2003; 31(5): 554 - 561. [Abstract] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gossett, K. A. Articles by Dean, J. H. Search for Related Content PubMed PubMed Citation Articles by Gossett, K. A. Articles by Dean, J. H. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?